For decades, we have been wondering whether suppression of the ovaries in addition to tamoxifen would improve the outcomes of women with hormone-receptor–positive premenopausal breast cancer. The SOFT trial was designed to address that question on the basis of a lot of data that suggested that it might help, especially in very young women.
SOFT Yields Hard Data on Hormone Therapy
